# Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting

> **NCT05266495** · — · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 3 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **OTHER:** Brolucizumab

## Key facts

- **NCT ID:** NCT05266495
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-13
- **Primary completion:** 2023-03-13
- **Final completion:** 2023-03-13
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Company Decision
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05266495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05266495, "Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05266495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*